Spring Bank Pharmaceuticals to Present Results from In Vivo Studies of SB 11285, a Novel STING agonist for Immuno-Oncology, at Keystone Symposia (Spring Bank Pharmaceuticals Inc)
(WorldNews Health)

(Source: Spring Bank Pharmaceuticals Inc) HOPKINTON, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc., (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced two abstracts on SB 11285, its most advanced STING (Stimulator of INterferon Genes) agonist product candidate for the potential treatment of certain cancers, have been accepted for presentation at the 2017 Keystone Symposia: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7), to be held at the...